Breast cancer is the most common cancer diagnosed in women worldwide and the second most common cancer diagnosed overall. Studies1,2 have found that most patients with early-stage disease will be cured, but there is a significant risk of both early and late recurrences. All treatments for breast cancer have some associated risks and adverse effects, some of which are permanent. Therefore, it is essential to develop methods to avoid overtreatment of patients by identifying those who are and are not at risk for relapse.
Karthikeyan S, Park BH. Circulating Tumor DNA as a Marker for Disease Relapse in Early-Stage Breast Cancer—Bad Blood. JAMA Oncol. 2019;5(10):1479–1480. doi:https://doi.org/10.1001/jamaoncol.2019.2047
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: